Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Ascites | Research

T2-weighted imaging and dynamic contrast‑enhanced imaging in predicting the prognosis in patients with acute-on-chronic liver failure

Authors: Yan Ni Du, Chun Shuang Guan, Zhi Bin Lv, Ming Xue, Yu Xue Xing, Ru Ming Xie

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Acute-on-chronic liver failure (ACLF) is a syndrome with high 28- and 90-day mortality rates. Magnetic resonance imaging (MRI) has been widely used to diagnose and evaluate liver disease. Our purpose is to determine the value of the imaging features derived from Gd-DTPA-enhanced MRI for predicting the poor outcome of patients with ACLF and develop a clinically practical radiological score.

Methods

This retrospective study comprised 175 ACLF patients who underwent Gd-DTPA-enhanced abdominal MRI from January 2017 to December 2021. The primary end-point was 90-day mortality. Imaging parameters, such as diffuse hyperintense of the liver on T2WI, patchy enhancement of the liver at the arterial phase, uneven enhancement of the liver at the portal vein phase, gallbladder wall edema, periportal edema, ascites, esophageal and gastric varix, umbilical vein patefac, portal vein thrombosis, and splenomegaly were screened. Cox proportional hazard regression models were used to evaluate prognostic factors and develop a prediction model. The accuracy of the model was evaluated by receiver operating characteristic (ROC) curves.

Results

During the follow-up period, 31 of the 175 ACLF patients died within 90 days. In the multivariate analysis, three imaging parameters were independently associated with survival: diffuse hyperintense on T2WI (p = 0.007; HR = 3.53 [1.40–8.89]), patchy enhancement at the arterial phase (p = 0.037; HR = 2.45 [1.06–5.69]), moderate ascites (vs. mild) (p = 0.006; HR = 4.12 [1.49–11.36]), and severe ascites (vs. mild) (p = 0.005; HR = 4.29 [1.57–11.71]). A practical radiological score was proposed, based on the presence of diffuse hyperintense (7 points), patchy enhancement (5 points), and ascites (6, 8, and 8 points for mild, moderate, and severe, respectively). Further analysis showed that a cut-off at 14 points was optimum to distinguish high-risk (score > 14) from the low-risk group (score ≤ 14) for 90-day survival and demonstrated a mean area under the ROC curve of 0.774 in ACLF patients.

Conclusions

Gd-DTPA-enhanced MR imaging features can predict poor outcomes in patients with ACLF, based on which we proposed a clinically practical radiological score allowing stratification of the 90-day survival.
Literature
1.
go back to reference Sarin SK, Choudhury A, Sharma MK, Maiwall R, Rahman S, Saigal S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. HEPATOL INT. 2019;13:353–90.CrossRefPubMed Sarin SK, Choudhury A, Sharma MK, Maiwall R, Rahman S, Saigal S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. HEPATOL INT. 2019;13:353–90.CrossRefPubMed
2.
go back to reference Bajaj JS, O’Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60:250–6.CrossRefPubMed Bajaj JS, O’Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60:250–6.CrossRefPubMed
3.
go back to reference Mezzano G, Juanola A, Cardenas A, Mezey E, Hamilton JP, Pose E, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut. 2021;71:148–55.CrossRefPubMed Mezzano G, Juanola A, Cardenas A, Mezey E, Hamilton JP, Pose E, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut. 2021;71:148–55.CrossRefPubMed
4.
go back to reference Cui H, Chen J, Na Q. Effect of hepatitis B virus infection on trophoblast cell line (HTR-8/SVneo) and choriocarcinoma cell line (JEG3) is linked to CD133-2 (AC141) expression. AM J TRANSL RES. 2016;8:3235–40.PubMedPubMedCentral Cui H, Chen J, Na Q. Effect of hepatitis B virus infection on trophoblast cell line (HTR-8/SVneo) and choriocarcinoma cell line (JEG3) is linked to CD133-2 (AC141) expression. AM J TRANSL RES. 2016;8:3235–40.PubMedPubMedCentral
5.
go back to reference Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–53.CrossRefPubMed Hernaez R, Sola E, Moreau R, Gines P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–53.CrossRefPubMed
6.
go back to reference Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–52.CrossRefPubMed Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–52.CrossRefPubMed
7.
go back to reference Zhang J, Gao S, Duan Z, Hu K. Overview on acute-on-chronic liver failure. FRONT MED-PRC. 2016;10:1–17.CrossRef Zhang J, Gao S, Duan Z, Hu K. Overview on acute-on-chronic liver failure. FRONT MED-PRC. 2016;10:1–17.CrossRef
8.
go back to reference Karvellas CJ, Francoz C, Weiss E. Liver transplantation in Acute-on-chronic liver failure. Transplantation. 2021;105:1471–81.CrossRefPubMed Karvellas CJ, Francoz C, Weiss E. Liver transplantation in Acute-on-chronic liver failure. Transplantation. 2021;105:1471–81.CrossRefPubMed
9.
go back to reference Hernaez R, Patel A, Jackson LK, Braun UK, Walling AM, Rosen HR. Considerations for prognosis, goals of Care, and Specialty Palliative Care for hospitalized patients with Acute-on‐chronic liver failure. Hepatology. 2020;72:1109–16.CrossRefPubMed Hernaez R, Patel A, Jackson LK, Braun UK, Walling AM, Rosen HR. Considerations for prognosis, goals of Care, and Specialty Palliative Care for hospitalized patients with Acute-on‐chronic liver failure. Hepatology. 2020;72:1109–16.CrossRefPubMed
10.
go back to reference Abdallah MA, Kuo Y, Asrani S, Wong RJ, Ahmed A, Kwo P, et al. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. J HEPATOL. 2021;74:1355–61.CrossRefPubMed Abdallah MA, Kuo Y, Asrani S, Wong RJ, Ahmed A, Kwo P, et al. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. J HEPATOL. 2021;74:1355–61.CrossRefPubMed
11.
go back to reference Zhang J, Li J, Chen Y, Ding M, Duan Z. Prognostic factors related to the Mortality rate of Acute-on-chronic liver failure patients. Diabetes, metabolic syndrome and obesity. 2021 14:2573–80. Zhang J, Li J, Chen Y, Ding M, Duan Z. Prognostic factors related to the Mortality rate of Acute-on-chronic liver failure patients. Diabetes, metabolic syndrome and obesity. 2021 14:2573–80.
12.
go back to reference Song DS, Kim TY, Kim DJ, Kim HY, Sinn DH, Yoon EL, et al. Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol. 2018;33:900–9.CrossRefPubMed Song DS, Kim TY, Kim DJ, Kim HY, Sinn DH, Yoon EL, et al. Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol. 2018;33:900–9.CrossRefPubMed
13.
go back to reference Mao Y, Wang J, Zhu Y, Chen J, Mao L, Kong W, et al. Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma. HEPATOBIL SURG NUTR. 2022;11:13–24.CrossRef Mao Y, Wang J, Zhu Y, Chen J, Mao L, Kong W, et al. Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma. HEPATOBIL SURG NUTR. 2022;11:13–24.CrossRef
14.
go back to reference Wang J, Tang S, Mao Y, Wu J, Xu S, Yue Q, et al. Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker. HEPATOL INT. 2022;16:627–39.CrossRefPubMed Wang J, Tang S, Mao Y, Wu J, Xu S, Yue Q, et al. Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker. HEPATOL INT. 2022;16:627–39.CrossRefPubMed
15.
go back to reference Tang S, Wu J, Xu S, Li Q, He J. Clinical-radiomic analysis for non-invasive prediction of liver steatosis on non-contrast CT: a pilot study. FRONT GENET. 2023 14. Tang S, Wu J, Xu S, Li Q, He J. Clinical-radiomic analysis for non-invasive prediction of liver steatosis on non-contrast CT: a pilot study. FRONT GENET. 2023 14.
16.
17.
go back to reference Romero M, Palmer SL, Kahn JA, Ihde L, Lin LM, Kosco A, et al. Imaging appearance in Acute Liver failure: correlation with Clinical and Pathology Findings. DIGEST DIS SCI. 2014;59:1987–95.CrossRefPubMed Romero M, Palmer SL, Kahn JA, Ihde L, Lin LM, Kosco A, et al. Imaging appearance in Acute Liver failure: correlation with Clinical and Pathology Findings. DIGEST DIS SCI. 2014;59:1987–95.CrossRefPubMed
18.
go back to reference Shu J, Zhao JN, Han FG, Tang GC, Chen X. Chronic hepatitis B: correlation of abnormal features on T2-weighted imaging and dynamic contrast-enhanced imaging with hepatic histopathology. Radiol Med. 2017;122:807–13.CrossRefPubMed Shu J, Zhao JN, Han FG, Tang GC, Chen X. Chronic hepatitis B: correlation of abnormal features on T2-weighted imaging and dynamic contrast-enhanced imaging with hepatic histopathology. Radiol Med. 2017;122:807–13.CrossRefPubMed
19.
go back to reference Kang TW, Kim M, Kim YK, Kim SH, Sinn DH, Kim K. The qualitative and quantitative image analysis of MR imaging in patients with acute-on-chronic liver failure. CLIN IMAG. 2018;47:18–24.CrossRef Kang TW, Kim M, Kim YK, Kim SH, Sinn DH, Kim K. The qualitative and quantitative image analysis of MR imaging in patients with acute-on-chronic liver failure. CLIN IMAG. 2018;47:18–24.CrossRef
20.
go back to reference Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and child-pugh-turcotte class B cirrhosis. LANCET ONCOL. 2017;18:e101–12.CrossRefPubMed Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and child-pugh-turcotte class B cirrhosis. LANCET ONCOL. 2017;18:e101–12.CrossRefPubMed
21.
go back to reference Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.CrossRefPubMed Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.CrossRefPubMed
22.
go back to reference Kim AI, Han SH, Tran DT, Sullivan P, Lassman C, Raman S, et al. Abdominal imaging can misdiagnose submassive hepatic necrosis as cirrhosis in acute liver failure. CLIN Transpl. 2013;27:E339–45.CrossRef Kim AI, Han SH, Tran DT, Sullivan P, Lassman C, Raman S, et al. Abdominal imaging can misdiagnose submassive hepatic necrosis as cirrhosis in acute liver failure. CLIN Transpl. 2013;27:E339–45.CrossRef
24.
go back to reference Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. LIVER INT. 2013;33:40–52.CrossRefPubMed Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. LIVER INT. 2013;33:40–52.CrossRefPubMed
25.
go back to reference Liu C, Shen Z, Ma H, Wang X, Wang X, Liu K, et al. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure. EUR RADIOL. 2022;32:3006–15.CrossRefPubMed Liu C, Shen Z, Ma H, Wang X, Wang X, Liu K, et al. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure. EUR RADIOL. 2022;32:3006–15.CrossRefPubMed
26.
go back to reference Hu C, Jiang N, Zheng J, Li C, Huang H, Li J, et al. Liver volume based prediction model for patients with hepatitis B virus-related acute‐on‐chronic liver failure. J HEPATO-BIL-PAN SCI; 2022. Hu C, Jiang N, Zheng J, Li C, Huang H, Li J, et al. Liver volume based prediction model for patients with hepatitis B virus-related acute‐on‐chronic liver failure. J HEPATO-BIL-PAN SCI; 2022.
27.
go back to reference Balcar L, Tonon M, Semmler G, Calvino V, Hartl L, Incicco S, et al. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep. 2022;4:100513.CrossRefPubMedPubMedCentral Balcar L, Tonon M, Semmler G, Calvino V, Hartl L, Incicco S, et al. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep. 2022;4:100513.CrossRefPubMedPubMedCentral
28.
go back to reference Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10.CrossRefPubMed Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10.CrossRefPubMed
29.
go back to reference Arroyo V, Angeli P, Moreau R, Jalan R, Claria J, Trebicka J, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J HEPATOL. 2021;74:670–85.CrossRefPubMed Arroyo V, Angeli P, Moreau R, Jalan R, Claria J, Trebicka J, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J HEPATOL. 2021;74:670–85.CrossRefPubMed
30.
go back to reference Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F et al. Acute-on-chronic liver failure in cirrhosis. NAT REV DIS PRIMERS. 2016 2. Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F et al. Acute-on-chronic liver failure in cirrhosis. NAT REV DIS PRIMERS. 2016 2.
31.
go back to reference Carbone I, Childs H, Aljizeeri A, Merchant N, Friedrich MG. Importance of reference muscle selection in quantitative Signal Intensity Analysis of T2-Weighted images of myocardial Edema using a T2 ratio Method. BIOMED RES INT. 2015;2015:232649.CrossRefPubMedPubMedCentral Carbone I, Childs H, Aljizeeri A, Merchant N, Friedrich MG. Importance of reference muscle selection in quantitative Signal Intensity Analysis of T2-Weighted images of myocardial Edema using a T2 ratio Method. BIOMED RES INT. 2015;2015:232649.CrossRefPubMedPubMedCentral
32.
go back to reference Kanematsu M, Danet MI, Leonardou P, Mastropasqua M, Mosetti MA, Braga L, et al. Early heterogeneous enhancement of the liver: magnetic resonance imaging findings and clinical significance. J MAGN RESON IMAGING. 2004;20:242–9.CrossRefPubMed Kanematsu M, Danet MI, Leonardou P, Mastropasqua M, Mosetti MA, Braga L, et al. Early heterogeneous enhancement of the liver: magnetic resonance imaging findings and clinical significance. J MAGN RESON IMAGING. 2004;20:242–9.CrossRefPubMed
Metadata
Title
T2-weighted imaging and dynamic contrast‑enhanced imaging in predicting the prognosis in patients with acute-on-chronic liver failure
Authors
Yan Ni Du
Chun Shuang Guan
Zhi Bin Lv
Ming Xue
Yu Xue Xing
Ru Ming Xie
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02920-2

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.